1. Home
  2. BVFL vs MOLN Comparison

BVFL vs MOLN Comparison

Compare BVFL & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BV Financial Inc.

BVFL

BV Financial Inc.

HOLD

Current Price

$19.74

Market Cap

172.7M

Sector

Finance

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

HOLD

Current Price

$4.64

Market Cap

158.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BVFL
MOLN
Founded
1873
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Savings Institutions
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
172.7M
158.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
BVFL
MOLN
Price
$19.74
$4.64
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$8.38
AVG Volume (30 Days)
14.3K
5.8K
Earning Date
01-23-2026
03-13-2026
Dividend Yield
N/A
N/A
EPS Growth
31.19
N/A
EPS
1.43
N/A
Revenue
$42,050,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$999.99
P/E Ratio
$13.64
N/A
Revenue Growth
10.94
N/A
52 Week Low
$13.53
$3.36
52 Week High
$19.88
$5.10

Technical Indicators

Market Signals
Indicator
BVFL
MOLN
Relative Strength Index (RSI) 63.60 59.79
Support Level $19.36 $4.45
Resistance Level $19.80 $4.74
Average True Range (ATR) 0.32 0.18
MACD 0.00 0.04
Stochastic Oscillator 89.93 85.23

Price Performance

Historical Comparison
BVFL
MOLN

About BVFL BV Financial Inc.

BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. The company offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, and business checking and certificates of deposit and IRA certificates of deposit. The Company's sources of revenue are derived from interest and dividends earned on loans and investment securities.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: